Glycosaminoglycans delay the progression of nephropathy in NIDDM

Diabetes Care

Volumn 20, Issue 5, 1997, Pages 819-823

  Solini, Anna ^b   Vergnani, Luciana ^b   Ricci, Franco ^b   Crepaldi, Gaetano ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; FIBRINOGEN; PLACEBO; SULODEXIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; HUMAN; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PROTEINURIA; TREATMENT OUTCOME; URINARY EXCRETION;

EID: 0030957881     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.5.819     Document Type: Article

References (35)

1. Viberti GC, Hill RD, Jarrett RJ: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet i:1430-1432, 1982
2. Mogensen CE, Christensen CK: Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311:89-93, 1984
3. Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Lancet ii:530-533, 1988
4. Zatz R, Meyer TW, Rennke HG, Brenner BM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic nephropathy. Proc Natl Acad Sci USA 82:5963-5967, 1985
5. Deckert T, Kofoed-Enevoldsen A, Vidal P, Norgaard K, Andreasen HB, Feldt-Rasmussen B: Size and charge selectivity of glomerular filtration in type I (insulin-dependent) diabetic patients with and without albuminuria. Diabetologia 36:244-251, 1993
6. Vlassara H, Brownlee M, Cerami A: Nonenzymatic glycosilation: role in the pathogenesis of diabetic complications. Clin Chem 32:B37-B41, 1986
7. Schleicher E, Nerlich A, Gerbitz K-D: Pathobiochemical aspects of diabetic nephropathy. Klin Wochenschr 66:783-882, 1988
8. Shimomura H, Spiro RG: Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes: decreased levels of heparan sulfate proteoglycan and laminin. Diabetes 36:374-381, 1987
9. Wu V-Y, Wilson B, Cohen MP: Disturbances in glomerular basement membrane glycosaminoglycans in experimental diabetes. Diabetes 36:679-683, 1987
10. 4 proteoglycan by heparin from glomeruli of streptozotocin-induced diabetic rats. Diabetes 38:130-139, 1989
11. Gambaro G, Cavazzana AO, Luzi P, Piccoli A, Borsatti A, Crepaldi G, Marchi E, Venturini AP, Baggio B: Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 42:285-291, 1992
12. Floege J, Eng E, Young BA, Couser WG, Johnson RJ: Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney Int 34:638-644, 1988
13. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985, p. 1-113 (Tech. Rep. Ser., no. 727)
14. Dunn PJ, Cole RA, Soeldner JS: Further development and automation of a high pressure liquid chromatography method for the determination of glycosilated hemoglobins. Metabolism 28:777-779, 1979
15. Keen H, Chlouverakis G: An immunoassay method for urinary albumin at low concentrations. Lancet ii:913-914, 1993
16. Veall N, Gibbs GP: The accurate determination of tracer clearance rates and equilibrium distribution volume from single injection plasma measurements using numerical analysis. In Radionuclides in Nephrology. Joekes AM, Constable AR, Brown NJG, Tranxe WN, Eds. London, Academic, 1982, p. 125-130
17. Deckert T, Feldt-Rasmussen B, Djurup R, Deckert M: Glomerular size and charge selectivity in insulin-dependent diabetes mellitus. Kidney Int 33:100-106, 1988
18. Viberti GC, Wiseman MJ: The kidney in diabetes: significance of the early abnormalities. Clin Endocrinol Metab 15:753-782, 1986
19. Kofoed-Enevoldsen A: Heparan sulphate in the pathogenesis of diabetic nephropathy. Diabetes Metab Rev 11:137-160, 1995
20. Gambaro G, Venturini AP, Noonan DM, Fries W, Re G, Garbisa S, Milanesi C, Pesanni A, Borsatti A, Marchi E, Baggio B: Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 46:797-806, 1994
21. Adler S, Eng G: Reversal of inhibition of rat glomerular epithelial cell growth by growth factors. Am J Pathol 136:557-563, 1990
22. 3H-thymidine labeling index in controls and heparin-treated rats following subtotal nephrectomy (Abstract). J Am Soc Nephrol 2:688, 1991
23. Myrup B, Hansen PM, Jensen T, Kofoed-Enevoldsen A, Feldt-Rasmussen B, Gram J, Kluft C, Jespersen J, Deckert T: Effect of low-dose heparin on urinary albumin excretion in insulin dependent diabetes mellitus. Lancet 345:421-422, 1995
24. Blajchman MA, Young E, Ofosu FA: Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann N Y Acad Sci 556:245-254, 1989
25. Rasch R: Prevention of diabetic glomerulopathy in streptozotocin diabetic rats: kidney size and glomerular volume. Diabetologia 16:125-128, 1979
26. Rasch R: Prevention of diabetic glomerulopathy in streptozotocin diabetic rats: the mesangial region. Diabetologia 17:243-248, 1979
27. Norgaard K, Storm B, Graae M, Feldt-Rasmussen B: Elevated albumin excretion and retinal changes in children with type 1 diabetes are related to long-term poor blood glucose control. Diabet Med 6:325-328, 1989
28. DCCT: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
29. Feldt-Rasmussen B, Mathiesen ER, Deckert T: Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet ii:1300-1304, 1986
30. Weiss MA, Ooi BS, Ooi YM, Engvall E, Ruoslahti E: Immunofluorescent localization of fibronectin in the human kidney Lab Invest 41:340-347, 1979
31. Kuboki K: Clinical significance of urinary excretion rate of fibronectin degradation products in diabetic nephropathy. J Jpn Diabetes Soc 31:457-462, 1989
32. Wilson SK, Solez K, Boitnott JK, Heptinstall RH: The effect of heparin treatment on hypertension and vascular lesions in stroke-prone spontaneously hypertensive rats. Am J Pathol 102:62-71, 1981
33. Ceriello A, Quatraro A, Ettorre M, Marchi E, Barbanti M, Giugliano D: Glycosaminoglycans administration decreases high fibrinogen plasma levels in diabetic patients. Diabetes NutrMetab 6:1-4, 1993
34. Castelluccio A, Bologna E: Effect of sulodexide on blood viscosity in patients with peripheral vascular disease. Curr Med Res Opin 12:325-331, 1991
35. Mauro M, Ferraro G, Palmieri G: Profibrinolytic and antithrombotic effects of sulodexide oral administration: double blind, crossover, placebo-controlled study. Curr Ther Res Clin Exp 51:342-350, 1992